2025-02-11 - Analysis Report
## Eli Lilly and Co (LLY) Stock Report

**0. Executive Summary:**

Eli Lilly and Co (LLY) is a leading pharmaceutical company.  This report analyzes LLY's recent performance against the S&P 500 (VOO), considering price movements, financial indicators (RSI, PPO), earnings, and financial statements.  LLY significantly outperformed the S&P 500, exhibiting strong growth but also high volatility and a potentially overbought condition.

**1. Performance Comparison with S&P 500:**

Eli Lilly and Co. (LLY) is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

* **LLY Cumulative Return:** 632.73%
* **VOO (S&P 500) Cumulative Return:** 120.05%
* **Return Difference:** 512.7%
* **Relative Divergence:** 81.5% (This indicates LLY's performance is in the 81.5th percentile relative to its historical performance compared to the S&P 500, considering the maximum and minimum divergence over time.)


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 9.0% | 4.3% | -19.0% | -0.0 | 67.9 |
| 2016-2018  | 47.0% | 4.3% | 29.0% | 0.0 | 95.4 |
| 2017-2019  | 60.0% | 8.7% | 29.0% | 1.1 | 110.8 |
| 2018-2020  | 90.0% | 11.1% | 62.0% | 0.3 | 145.2 |
| 2019-2021  | 145.0% | 11.1% | 74.0% | 0.2 | 241.1 |
| 2020-2022  | 196.0% | 11.1% | 188.0% | 0.2 | 323.7 |
| 2021-2023  | 300.0% | 10.8% | 277.0% | 0.3 | 520.8 |
| 2022-2024  | 396.0% | 11.1% | 363.0% | 0.3 | 694.3 |
| 2023-2025  | 389.0% | 11.1% | 328.0% | 0.3 | 781.4 |

LLY has consistently outperformed the market (as indicated by the positive alpha values in most years) and exhibits moderate beta (market sensitivity).  The CAGR (Compound Annual Growth Rate) shows substantial growth, particularly in recent years.  However, the MDD (Maximum Drawdown) indicates significant potential for short-term losses.

**2. Recent Price Movement:**

* **Closing Price:** $868.88
* **Previous Close:** $878.31
* **5-Day Moving Average:** $857.16
* **20-Day Moving Average:** $798.43
* **60-Day Moving Average:** $787.97

The price is slightly below the 5-day moving average, suggesting a recent minor downturn.  However, it sits significantly above both the 20-day and 60-day moving averages, indicating a strong upward trend over the medium and longer term.  The recent price change (-1.07%) represents a minor correction after a period of strong gains.


**3. Technical Indicators:**

* **RSI:** 85.31 –  This is in overbought territory, suggesting the stock may be due for a correction.
* **PPO:** 1.25 – A positive PPO indicates bullish momentum.
* **20-Day Relative Divergence Change:** +7.1% –  This confirms a short-term upward trend.
* **Expected Return (2+ years):** 94.8% –  This indicates a significant expected outperformance compared to the S&P 500 with long-term investment.  The recent minor price drop does not significantly alter this long-term outlook.


**4. Recent Earnings Analysis:**

| Date       | EPS   | Revenue      |
|------------|-------|---------------|
| 2024-10-30 | $1.08 | $11.44B       |
| 2024-08-08 | $3.29 | $11.30B       |
| 2024-04-30 | $2.49 | $8.77B        |
| 2023-11-02 | -$0.06| $9.50B        |
| 2023-10-30 | -$0.06| $9.50B        |


Earnings have shown volatility, with significant spikes in EPS in Q2 and Q3 2024.  The negative EPS in Q4 2023 and Q4 2024 requires further investigation into the underlying causes. Revenue generally shows a positive trend.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue    | Profit Margin |
|---------|------------|---------------|
| 2024-09-30 | $11.44B   | 81.02%        |
| 2024-06-30 | $11.30B   | 80.80%        |
| 2024-03-31 | $8.77B    | 80.91%        |
| 2023-12-31 | $9.35B    | 80.88%        |
| 2023-09-30 | $9.50B    | 80.42%        |

Revenue is relatively stable, showing slight fluctuations. Profit margins are consistently high, indicating strong profitability.


**Capital and Profitability:**

| Quarter | Equity     | ROE       |
|---------|------------|-----------|
| 2024-09-30 | $14.24B   | 6.81%     |
| 2024-06-30 | $13.56B   | 21.88%    |
| 2024-03-31 | $12.81B   | 17.51%    |
| 2023-12-31 | $10.77B   | 20.33%    |
| 2023-09-30 | $11.22B   | -0.51%    |

Equity shows a generally upward trend. ROE (Return on Equity) is highly variable, with some quarters exhibiting exceptionally high returns and others showing negative returns. This requires further investigation.


**6. Overall Analysis:**

LLY has demonstrated exceptional performance compared to the S&P 500, driven by strong revenue and high profit margins.  However, the high RSI suggests an overbought condition, and the recent price drop indicates potential for a short-term correction.  The high expected return (94.8%) for long-term investors remains attractive despite the recent dip and the volatility observed in EPS and ROE.  Further analysis of the causes behind the negative EPS and fluctuating ROE is crucial for a complete assessment of LLY's financial health.  Careful consideration of risk tolerance is advised, given the potential for short-term corrections due to the stock's high volatility.
